IDEXX LABORATORIES INC /DE — Director's Dealing 2018

May 21, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2018-05-09

Reporting Person: Lane Michael (Corporate Vice President)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3384	Direct
Common Stock	592	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Unit	$		Common Stock (3110)		Direct
Incentive Stock Option (right-to-buy)	$45.84	2023-02-13	Common Stock (3332)		Direct
Non-Qualified Stock Option (right-to-buy)	$62	2024-02-13	Common Stock (2112)		Direct
Incentive Stock Option (right-to-buy)	$62	2024-02-13	Common Stock (2010)		Direct
Non-Qualified Stock Option (right-to-buy)	$79.54	2025-02-13	Common Stock (2362)		Direct
Incentive Stock Option (right-to-buy)	$79.54	2025-02-13	Common Stock (1386)		Direct
Non-Qualified Stock Option (right-to-buy)	$67.85	2026-02-13	Common Stock (10749)		Direct
Incentive Stock Option (right-to-buy)	$67.85	2026-02-13	Common Stock (2072)		Direct
Non-Qualified Stock Option (right-to-buy)	$141.6	2027-02-13	Common Stock (10386)		Direct
Incentive Stock Option (right-to-buy)	$141.6	2027-02-13	Common Stock (706)		Direct
Non-Qualified Stock Option (right-to-buy)	$178.26	2028-02-13	Common Stock (9434)		Direct
Incentive Stock Option (right-to-buy)	$178.26	2028-02-13	Common Stock (560)		Direct

Footnotes

F1: Includes 598 shares held in the reporting person's IRA account.

F2: Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.

F3: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").

F4: Grant of option to buy 1,661 shares of Issuer common stock that vested in one installment on February 14, 2018, without giving effect to the Stock Split.

F5: Grant of option to buy 1,056 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2015, without giving effect to the Stock Split.

F6: Grant of option to buy 1,005 shares of Issuer common stock that vests in one installment on February 14, 2019, without giving effect to the Stock Split.

F7: Grant of option to buy 1,181 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split.

F8: Grant of option to buy 693 shares of Issuer common stock that vests in one installment on February 14, 2020, without giving effect to the Stock Split.

F9: Grant of option to buy 10,749 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2017.

F10: Grant of option to buy 2,072 shares of Issuer common stock that vests as to 1 share on February 14, 2017, February 14, 2018 and February 14, 2020, respectively, and as to the remainder on February 14, 2021.

F11: Grant of option to buy 10,386 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2018.

F12: Grant of option to buy 706 shares of Issuer common stock that vests in one installment on February 14, 2022.

F13: Grant of option to buy 9,434 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2019.

F14: Grant of option to buy 560 shares of Issuer common stock that vests in one installment on February 14, 2023.

F15: The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.